Latest news
- Business22 February 2022
Adalvo Announces Successful Pivotal BE Outcome For Apixaban 5mg Film Coated Tablets
Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Apixaban 5mg Film Coated Tablets.
- Business17 February 2022
CellResearch Corporation (CRC) has been awarded SME Designation by the European Medicines Agency (EMA)
Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), a clinical stage company developing innovative stem cell therapies, announced today that the European Commission and the European Medicines...
- Business27 January 2022
Adalvo announces successful launch of Icatibant
Adalvo is pleased to announce that we have successfully launched Icatibant in 14 markets. This product is a complex injectable peptide, forming part of our high-value product portfolio offering to...
- Business05 January 2022
Adalvo announces successful pivotal BE outcome for Vortioxetine Film-Coated Tablets
As this new year begins, Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Vortioxetine Film-Coated Tablets.
- Business07 December 2021
Adalvo enters into strategic collaboration deal with Naari Pharma
Adalvo is thrilled to announce that we have entered into a strategic collaboration deal with Naari Pharma, a vertically integrated women’s health pharmaceutical business, based in Bangalore, India.
- Business02 December 2021
Adalvo announces successful DCP submission of Nitrofurantoin ER 100mg capsules
Adalvo is pleased to announce that we have successfully submitted our EU DCP procedure for Nitrofurantoin ER 100mg Capsules, another differentiated product within our portfolio, that was developed based on...
- Business26 November 2021
Adalvo recognized as one of the Best Workplaces for 2021
Adalvo, one of the leading B2B global pharmaceutical companies, with commercial partnerships in more than 100 countries, have been certified as one of the Best Places to Work for 2021!...
- Business26 November 2021
Innobic (Asia) and Aztiq co-invest in a US$475 deal to form a leading global pharma platform
The Consortium jointly, through Aztiq II HoldCo Limited, will acquire a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus and Adalvo.
- Business15 November 2021
Anil Okay is recognized as Leader of the Year by the Global Generics & Biosimilars committee
We are pleased to announce that our General Manager, Anil Okay has been awarded the Leader of the Year Award 2021, by the Global Generics & Biosimilar Awards committee.
- Business11 November 2021
Adalvo Announces Successful Pivotal BE Outcome Of Nintedanib 100, 150mg Soft Gel Capsules
Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Nintedanib 100mg & 150mg soft gel capsules. We are now moving ahead into dossier completion, and...
- Business08 November 2021
Adalvo announces successful Pivotal BE outcome of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablet
Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. We are now moving ahead into dossier completion and...
- Business04 November 2021
Adalvo announces successful DCP submission for Gralise®
We are proud to announce the successful submission of our DCP procedure for our distinguished hybrid / 505(b)(2) asset Gralise®. We expect to launch this high- value asset in H1...
- Business02 November 2021
Adalvo announces successful DCP submission for Liraglutide pre-filled pen
We are extremely delighted to announce that we successfully submitted our DCP procedure for Liraglutide 6mg/ml pre-filled pen on Friday 29th October, which has been developed in close...
- Business13 October 2021
CellResearch Corporation has been awarded an Innovation Passport for CorLiCyte™
Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has been awarded an Innovation Passport for CorLiCyte™, by the UK’s regulatory agencies (MHRA, NICE, SMC), becoming one of...
- Business07 October 2021
Adalvo announces successful DCP submission for Lisdexamfetamine Oral Solution
Adalvo is delighted to announce the successful submission of our DCP procedure for Lisdexamfetamine Oral Solution 10mg / ml which has been developed in close collaboration with Laboserve & Pharma-Data....
- Business28 September 2021
Adalvo announces successful DCP closure for Icatibant
Adalvo is pleased to announce the successful closure on our DCP procedure for our Icatibant development, a complex injectable peptide product, forming part of our high-value product portfolio offering to...
- Business14 September 2021
Adalvo announces successful DCP filing for Teriflunomide
Adalvo is pleased to announce the successful DCP filing on its Teriflunomide development, a new addition to our high-value product portfolio offering to our partners.
- Business26 August 2021
Adalvo announces successful Pivotal BE outcome of Lisdexamfetamine Oral Solution 10mg / ml
Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine Oral Solution 10mg / mlwhich has been developed in close collaboration with Laboserve & Pharma-Data.
- Business18 August 2021
Adalvo announces completion of Phase III patient enrollment for Dimethyl Fumarate 30 mg / 120 mg
Adalvo is pleased to announce that we have completed our patient enrollment of our Phase 3 clinical study, to assess the safety and efficacy of Dimethyl Fumarate 30 mg /...
- Business05 August 2021
Adalvo and Hansoh Pharma enter into an exclusive license partnership
Adalvo and Jiangsu Hansoh Pharma, a leading R&D-driven pharmaceutical company in China, are pleased to announce that they have entered into an strategic partnership for the commercialization of Fulvestrant pre-filled injection...
- Business29 July 2021
Lotus Enhanced Oncology Pipeline
Adalvo is the only B2B platform with a real selected boutique approach to portfolio. We are proud to offer products from all the major pharmaceutical domains, oncology being one of...